RxDoctor Payments Data

Michael Honan, MD

Internal Medicine · Pekin, ILNPI 1255424750

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 78 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$214
  • Novartis$156
  • AbbVie$104
  • Novo Nordisk$73
  • Urovant Sciences Inc$47
  • Vanda Pharmaceuticals Inc.$47
  • plus $507 from 17 others

What the payments were for

  • Food & beverage$1,10196%
  • Education$474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,148 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$240,279
Medicare patients
1,460
Services billed
5,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban474$247,607
JardianceEmpagliflozin216$137,777
TrulicityDulaglutide39$63,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$57,721
XareltoRivaroxaban81$51,689
JanuviaSitagliptin Phosphate67$43,908
OzempicSemaglutide44$41,642
MyrbetriqMirabegron89$38,803
TradjentaLinagliptin59$22,585
Posaconazole17$20,430
Breo ElliptaFluticasone/Vilanterol31$17,983
Combivent RespimatIpratropium/Albuterol Sulfate21$14,710
Tresiba Flextouch U-200Insulin Degludec50$13,885
FarxigaDapagliflozin Propanediol17$13,484
LinzessLinaclotide19$12,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$214$247,607474 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat$24$181,745308 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$40$84,59898 claims
Johnson & JohnsonXarelto$41$51,68981 claims
Novo NordiskOzempic$73$41,64244 claims
Astellas Pharma US IncMyrbetriq$42$38,80389 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$12$28,59854 claims
AbbVieLinzess$104$12,32319 claims
NovartisEntresto$156$9,58218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Pekin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →